Over the last four years, Avextra has built one of the only vertically integrated EU operations from genetic selection and cultivation to sales and distribution. By effectively and responsibly deploying capital, we’ve built valuable assets strategically across Europe and are already present in some of the biggest EU markets.
Meet Avextra: Europe’s leader in Cannabis-based medicine
Assets strategically developed across Europe
via high calibre partners
Avextra controls the entire value chain
From genetic selection through to product innovation
Our products are already present in 4 of the biggest EU markets with expansion plans in place. We have one of the largest sales team in Germany, equipped with exceptional connections.
Here you see some placeholder text to explain the picture.
Avextra Unveils its Alliance for Evidence and Announces its Support of BELCANTO: A Clinical Trial for Oncology Patients
Bensheim, 18.10.2023 – Avextra is launching its Alliance for Evidence-based Cannabis Medicine: a platform focused on collaborating with healthcare professionals and researchers to generate real-world patient data with the aim…
Avextra Signs Distribution Agreements with Pharmaceutical Partners and Commences Exports of Cannabis-based Medicines to Switzerland and Austria
Avextra has signed distribution agreements with two pharmaceutical distribution partners in Switzerland and one partner in Austria Avextra begins exports of standardized cannabis-based medicines from its EU-GMP German facility to…
Avextra has successfully exported EU-GMP standardised cannabis extracts manufactured at its German facility to its distribution partner in Italy Avextra extracts are the first Made in Germany products to serve…
Today marked a historic day in Germany as major strides were made in removing the stigma surrounding this plant. Martha Lurther, CSO at Avextra shares her thoughts on Germany’s plans.…
Exclusive research partnership in oncology
Strategic research collaboration with the largest pain society in the EU.
50/50 owned UK based clinic with IPS Pharma.
Our formulation partner and shareholder. Leading New York licensed cannabis company.
Leveraging membership in pharmaceutical industry association
Research collaboration on toxicology
We are always looking to connect with those who share our vision. If you’re interested in receiving a detailed deck and discovering how you can be part of our success, please contact us today.